Business Context and Reporting Period
This Form 8-K filing by Aligos Therapeutics, Inc. (ALGS) reports a corporate governance event effective April 26, 2021. The Company is an emerging growth company incorporated in Delaware.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on board composition and director compensation.
Material Changes
- Board Expansion: The Board of Directors increased the number of authorized directors from eight to nine.
- New Appointment: James Scopa was appointed as a Class I director to fill the newly created seat. His term expires at the 2021 annual meeting of stockholders.
Compensation and Governance Details
Under the Company's non-employee director compensation program, Mr. Scopa will receive:
- A $35,000 annual retainer, prorated for the remainder of 2021.
- An automatic initial grant of a stock option to purchase 30,000 shares of Common Stock under the 2020 Incentive Award Plan.
- Execution of the Company's standard indemnification agreement for directors and executive officers.
Investor Verification Checklist
- Verify the total number of authorized directors is now nine.
- Confirm the specific vesting schedule and exercise price for the 30,000 stock options granted to Mr. Scopa by reviewing the 2020 Incentive Award Plan.
- Review the full text of the non-employee director compensation program filed as Exhibit 10.11 to the Form S-1 (October 9, 2020).
- Check the Company's Form S-1 Exhibit 10.12 for the standard indemnification agreement terms.